Login to Your Account



FDA Issues CRL for Alexza Pharmaceuticals' Adasuve

By Catherine Shaffer
Staff Writer

Monday, May 7, 2012

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) stock closed at 49 cents Friday, a loss of 12 cents, or about 20 percent, on news that the FDA had issued a complete response letter for its new drug application for Adasuve (loxapine) inhalation powder for agitation in schizophrenia and bipolar disorder.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription